206550-68-7

Upstream product

• 223251-13-6 [4-[2-(1-piperidinyl)ethoxy]phenyl]methanol 
• 52191-15-8 4-(2-bromoethyloxy)benzaldehyde 
• 123-08-0 4-hydroxy-benzaldehyde 
• 38459-72-2 (4-(2-bromoethoxy)phenyl)methan-1-ol 

Downstream Products

• 206552-16-1 2-{(4-methoxy-benzenesulfonyl)-[4-(2-piperidin-1-yl-ethoxy)-benzyl]-amino}-3-methyl-benzoic acid methyl ester 
• 212769-74-9 2-methyl-3-[4-(2-piperidin-1-yl-ethoxy)-phenyl-2-(thiophene-2-sulfonyl)]-propionic acid ethyl ester 
• 212768-92-8 2-(4-methoxy-benzenesulfonyl)-2-methyl-3-[4-(2-piperidin-1-yl-ethoxy)-phenyl]-propionic acid ethyl ester 
• 566899-84-1 2-(octane-1-sulfonyl)-3-[4-(2-piperidin-1-ylethoxy)phenyl]propionic acid ethyl ester 
• 212769-33-0 2-(4-n-butoxybenzenesulfonyl)-2-methyl-3-[4-(2-piperidin-1-ylethoxy)phenyl]propionic acid ethyl ester 
• 859392-85-1 7-methoxy-10-[4-(2-piperidin-1-yl-ethoxy)-benzyl]-10H-benzo[4,5]thieno[3,2-b]indole 
• 859392-87-3 3,7-dimethoxy-10-[4-(2-piperidin-1-yl-ethoxy)-benzyl]-10H-benzo[4,5]thieno[3,2-b]indole 
• 212769-84-1 2-(4-bromo-benzenesulfonyl)-2-methyl-3-[4-(2-piperidine-1-yl-ethoxy)-phenyl]-propionic acid ethyl ester 
• 212769-72-7 2-methyl-2-(2-methyl-furan-3-sulfonyl)-3-[4-(2-piperidin-1-yl-ethoxy)-phenyl]-propionic acid ethyl ester 
• 212769-76-1 2-(octane-1-sulfonyl)-3-[4-(2-piperidin-4-yl-ethoxy)phenyl]propionic acid ethyl ester 
• 287200-93-5 4-{ [4-(2-Butynyloxy)phenyl]sulfonyl}-1-[4-(2-piperidin-1-yl-ethoxy)-benzyl]-piperidine-4-carboxylic acid hydroxyamide 
• 328933-49-9 2,2-Dimethyl-propionic Acid 4-{5-benzyloxy-3-methyl-1-[4-(2-piperidin-1-yl-ethoxy)-benzyl]-1H-indol-2-yl }-phenyl Ester 
• 566899-85-2 2-(octane-1-sulfonyl)-3-[4-(2-piperidin-1-ylethoxy)phenyl]propionic acid 

Relevant academic research and scientific papers

Benzothieno[3,2-b]indole derivatives as potent selective estrogen receptor modulators

A series of estrogen receptor ligands based on benzothieno[3,2-b]indole were synthesized and their binding affinity for estrogen receptor subtypes (ERα and ERβ) and effects on mouse uterus and bone were evaluated. Some of these compounds showed strong bin

N-SUBSTITUTED INDOLINES AS ESTROGENIC AGENTS

The present invention provides compounds of formula (I) wherein R1 is H or benzyl; R2 is H, -OH, or -O-benzyl; R3, R4, and R5 are independently selected from H, halogen, cyano, C1-C6 alkyl (straight chain or branched), trifluoromethyl, -OH or the C1-C12 e

N-substituted indolines as estrogenic agents

This invention provides compounds of the formula wherein R1, R2, R3, R4, R5, R6, R7, X, n and Y, are as defined in the specification, or a pharmaceutically acceptable salt thereof, as well as pharmaceutical compositions and methods utilizing the compounds for treating or preventing disease states or syndromes which are caused or associated with an estrogen deficiency or an excess of estrogen utilizing these compounds.

THE PREPARATION AND USE OF ORTHO-SULFONAMIDO ARYL HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASE AND TACE INHIBITORS

The present invention relates to the discovery of novel, low molecular weight, non-peptide inhibitors of matrix metalloproteinases (e.g. gelatinases, stromelysins and collagenases) and TNF- alpha converting enzyme (TACE, tumor necrosis factor- alpha converting enzyme) which are useful for the treatment of diseases in which these enzymes are implicated such as arthritis, tumor growth and metastasis, angiogenesis, tissue ulceration, abnormal wound healing, periodontal disease, bone disease, proteinuria, aneurysmal aortic disease, degenerative cartilage loss following traumatic joint injury, demyelinating diseases of the nervous system, graft rejection, cachexia, anorexia, inflammation, fever, insulin resistance, septic shock, congestive heart failure, inflammatory disease of the central nervous system, inflammatory bowel disease, HIV infection, age related macular degeneration, diabetic retinopathy, proliferative vitreoretinopathy, retinopathy of prematurity, ocular inflammation, keratoconus, Sjogren's syndrome, myopia, ocular tumors, ocular angiogenesis/neovascularization. The TACE and MMP inhibiting ortho-sulfonamido aryl hydroxamic acids of the present invention are represented by formula (I) where the hydroxamic acid moiety and the sulfonamido moiety are bonded to adjacent carbons on group A where: A is phenyl or naphthyl, optionally substituted by R, R, R and R; Z is aryl, heteroaryl, or heteroaryl fused to a phenyl, where aryl is phenyl or naphthyl optionally substituted by R, R, R and R; heteroaryl is a 5-6 membered heteroaromatic ring having from 1 to 3 heteroatoms independently selected from N, O and S, and optionally substituted by R, R, R and R; and when heteroaryl is fused to phenyl, either or both of the rings can be optionally substituted by R, R, R and R; and R, R, R, R, R, R, R, R and R are described in the specification, and the pharmaceutically acceptable salts thereof and the optical isomers and diastereomers thereof.

PREPARATION AND USE OF ORTHO-SULFONAMIDO ARYL HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASE AND TACE INHIBITORS

The present invention relates to the discovery of novel, low molecular weight, non-peptide inhibitors of matrix metalloproteinases (e. g. gelatinases, stromelysins and collagenases) and TNF-α converting enzyme (TACE, tumor necrosis factor-α converting enzyme) which are useful for the treatment of diseases in which these enzymes are implicated such as arthritis, tumor growth and metastasis, angiogenesis, tissue ulceration, abnormal wound healing, periodontal disease, bone disease, proteinuria, aneurysmal aortic disease, degenerative cartilage loss following traumatic joint injury, demyelinating diseases of the nervous system, graft rejection, cachexia, anorexia, inflammation, fever, insulin resistance, septic shock, congestive heart failure, inflammatory disease of the central nervous system, inflammatory bowel disease, HIV infection, age related macular degeneration, diabetic retinopathy, proliferative vitreoretinopathy, retinopathy of prematurity, ocular inflammation, keratoconus, Sjogren's syndrome, myopia, ocular tumors, ocular angiogenesis/neovascularization. The TACE and MMP inhibiting ortho-sulfonamido aryl hydroxamic acids of the present invention are represented by the formula STR1 where the hydroxamic acid moiety and the sulfonamido moiety are bonded to adjacent carbons on group A.